Literature DB >> 2961558

Carbamazepine side effects in children and adults.

J M Pellock1.   

Abstract

Most of the side effects associated with carbamazepine (Tegretol, USP, Geigy Pharmaceuticals) therapy are mild, transient, and reversible with an adjustment in dosage or rate of dosage increase. Direct reports to Geigy Pharmaceuticals for the period 1975 to 1986 totaled 371 hematologic, 396 dermatologic, and 156 hepatic and pancreatic occurrences out of more than 4 million patients treated. These include 27 cases of aplastic anemia and 10 of agranulocytosis. In a study of the incidence of side effects in 220 children below the age of 16 years who were receiving carbamazepine, drowsiness, loss of coordination, and vertigo were the most commonly observed side effects and were almost always transient and dose related. The findings of this study are comparable with those of other series assessing carbamazepine-associated adverse reactions in children and adults. Overall, 30 to 50% of children and adults were reportedly free of side effects in these studies. Recommendations for carbamazepine therapy include education of patients and parents in the nature and likelihood of possible serious adverse reactions and routine monitoring to detect laboratory abnormalities.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2961558     DOI: 10.1111/j.1528-1157.1987.tb05780.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  34 in total

1.  Hypersensitivity to topiramate sprinkle capsules does not preclude the use of topiramate tablets.

Authors:  Dorothy Marsden; Susan E Libretto
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

2.  Alleviation of Trigeminal Nociception Using p75 Neurotrophin Receptor Targeted Lentiviral Interference Therapy.

Authors:  Valerie B O'Leary; Marie O'Connell; Inga Antyborzec; Vasilis Ntziachristos; J Oliver Dolly; Saak V Ovsepian
Journal:  Neurotherapeutics       Date:  2018-04       Impact factor: 7.620

3.  Childhood Epilepsy : Current Therapeutic Recommendations.

Authors:  J T Gilman; M Duchowny
Journal:  CNS Drugs       Date:  1994-03       Impact factor: 5.749

4.  Association of carbamazepine major metabolism and transport pathway gene polymorphisms and pharmacokinetics in patients with epilepsy.

Authors:  Yogita Ghodke Puranik; Angela K Birnbaum; Susan E Marino; Ghada Ahmed; James C Cloyd; Rory P Remmel; Ilo E Leppik; Jatinder K Lamba
Journal:  Pharmacogenomics       Date:  2013-01       Impact factor: 2.533

5.  The use of transgenic cell lines for evaluating toxic metabolites of carbamazepine.

Authors:  C R Valentine; J L Valentine; J Seng; J Leakey; D Casciano
Journal:  Cell Biol Toxicol       Date:  1996-06       Impact factor: 6.691

Review 6.  CNS adverse events associated with antiepileptic drugs.

Authors:  Gina M Kennedy; Samden D Lhatoo
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

7.  Carbamazepine-hypersensitivity: assessment of clinical and in vitro chemical cross-reactivity with phenytoin and oxcarbazepine.

Authors:  M Pirmohamed; A Graham; P Roberts; D Smith; D Chadwick; A M Breckenridge; B K Park
Journal:  Br J Clin Pharmacol       Date:  1991-12       Impact factor: 4.335

8.  Acute liver failure induced by carbamazepine.

Authors:  N Hadzić; B Portmann; E T Davies; A P Mowat; G Mieli-Vergani
Journal:  Arch Dis Child       Date:  1990-03       Impact factor: 3.791

9.  Carbamazepine-induced skin rash in children with epilepsy.

Authors:  T Konishi; Y Naganuma; K Hongo; M Murakami; M Yamatani; T Okada
Journal:  Eur J Pediatr       Date:  1993-07       Impact factor: 3.183

10.  Carbamazepine extended-release capsules in bipolar disorder.

Authors:  Richard H Weisler
Journal:  Neuropsychiatr Dis Treat       Date:  2006-03       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.